posted on January 1, 2007 - 3:57pm
PTC124 trial shows promise in boys with Duchenne MD Biotechnology company PTC Therapeutics of South Plainfield, N.J., which has received some $1.5 million from MDA for drug development, announced encouraging results in October from the phase 2 trial of its experimental compound PTC124 in 26 boys with Duchenne muscular dystrophy (DMD).

New content is being added every day. Please check back again.